CJC-1295 (No DAC) FAQ: Sourcing, Purity, Storage & Shipping

1. Overview & Primary Biological Mechanisms

CJC-1295 (No DAC), also known as Modified GRF 1-29, is a synthetic 29-amino-acid peptide analog of naturally occurring Growth Hormone-Releasing Hormone (GHRH). Preclinical studies suggest that CJC-1295 (No DAC) binds selectively to the GHRH receptor on pituitary somatotropes. In animal models, this activation stimulates pulsatile growth hormone secretion, which subsequently elevates systemic insulin-like growth factor 1 (IGF-1) concentrations relevant to tissue repair research.

Q: What is CJC-1295 (No DAC) and what is its primary biological mechanism? A: CJC-1295 (No DAC) is a 29-amino-acid GHRH analog. In preclinical models, it binds to GHRH receptors in the anterior pituitary, stimulating the pulsatile release of endogenous growth hormone. Researchers utilize CJC-1295 (No DAC) to evaluate physiological signaling cascades, cell proliferation, and downstream IGF-1 expression during tissue repair studies.

Q: What is the structural difference between CJC-1295 with DAC and CJC-1295 (No DAC)? A: The primary difference lies in the Drug Affinity Complex (DAC) modification. CJC-1295 with DAC contains a Lysine-maleimidopropionic acid adduct that covalently binds to serum albumin, extending half-life to several days in vivo. Conversely, CJC-1295 (No DAC) lacks this complex, preserving short, natural pulsatile GH release kinetics for acute laboratory experimentation.

2. Chemical Specifications & Molecular Identity

Precision in peptide synthesis is vital for reproducible experimental outcomes. CJC-1295 (No DAC) contains four amino acid substitutions relative to wild-type GHRH (1-29), specifically at positions 2, 8, 15, and 27 (D-Ala2, Gln8, Ala15, Leu27). These modifications resist enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV), conferring greater metabolic stability in vitro compared to native endogenous GHRH.

Q: What are the chemical specifications of PX1 Research CJC-1295 (No DAC)? A: PX1 Research supplies CJC-1295 (No DAC) as a sterile lyophilized powder with a empirical formula of C152H252N44O42 and a molecular weight of 3367.97 Da. Synthesized via solid-phase peptide synthesis (SPPS) in ISO 17025 accredited facilities, it retains high structural stability for cell culture and biochemical assay research.

Q: Why are amino acid substitutions incorporated into Modified GRF 1-29? A: Natural GHRH (1-29) undergoes rapid cleavage by DPP-IV enzymes in biological fluids. The D-Alanine substitution at position 2 prevents enzymatic degradation, extending the functional half-life of the peptide in experimental assays from minutes to approximately 30 minutes, allowing controlled observation of pituitary receptor binding.

3. Sourcing, Manufacturing, and Purity Standards

Evaluating research peptide suppliers requires strict verification of manufacturing practices and analytical transparency. PX1 Research manufactures all catalog peptides in USA-based, cGMP-compliant facilities to ensure absolute lot-to-lot consistency, low residual counterion levels, and zero biological contaminants.

Q: Where is PX1 Research CJC-1295 (No DAC) manufactured? A: All CJC-1295 (No DAC) vials are manufactured in state-of-the-art laboratory facilities located in the USA. Production adheres strictly to ISO 9001 and GMP standards, minimizing batch variations and providing verified high-purity compounds for academic, pharmaceutical, and institutional researchers across North America.

Q: What purity grade does PX1 Research guarantee for CJC-1295 (No DAC)? A: PX1 Research guarantees a minimum purity threshold of 99.0% for every production lot. High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) assays confirm chemical identity, correct molecular weight, and absence of truncated peptide sequences prior to inventory release across our full catalog of all research peptides.

4. Quality Control, Analytical Verification, and COAs

Rigorous analytical testing ensures that experimental variables remain controlled during in vitro and animal studies. Every batch of PX1 Research material undergoes multi-stage testing, with results documented on lot-specific documentation accessible via our centralized COA verification directory.

Q: How can researchers verify the Certificate of Analysis (COA) for CJC-1295 (No DAC)? A: Researchers can access lot-specific Certificates of Analysis directly on our dedicated COA lookup page. Each report displays full High-Performance Liquid Chromatography (HPLC) chromatograms, Mass Spectrometry (MS) spectrographs, and total purity percentages validated by independent, ISO 17025 accredited third-party laboratories.

Q: What endotoxin standards are enforced for PX1 Research CJC-1295 (No DAC)? A: Every production lot undergoes Chromogenic LAL (Limulus Amebocyte Lysate) testing to confirm endotoxin levels remain below 0.01 EU/mg. Low endotoxin content is critical for preventing non-specific immune responses or cytotoxic artifacts in cell cultures and animal model tissue assays.

5. Laboratory Reconstitution & Solvent Selection

Lyophilized peptides must be properly reconstituted prior to introducing them into bioassays. For working calculations and volumetric determination, researchers should utilize our interactive reconstitution calculator to maintain precision.

Q: What solvent is recommended for reconstituting CJC-1295 (No DAC)? A: Standard laboratory protocol recommends reconstituting lyophilized CJC-1295 (No DAC) in sterile Bacteriostatic Water (0.9% benzyl alcohol) for multi-use laboratory assays, or sterile 0.9% Normal Saline for immediate single-use cell culture procedures. Gently swirl the vial without aggressive vortexing to prevent protein denaturing.

Q: How do researchers calculate stock concentrations for laboratory experimentation? A: Researchers determine target concentration by dividing total peptide mass (e.g., 2 mg or 5 mg) by the volume of diluent added. To avoid mathematical error and ensure exact unit-to-volume dosing in preclinical models, researchers should use the automated PX1 reconstitution calculator.

6. Storage, Stability, and Shelf-Life Guidelines

Peptide stability depends on temperature, exposure to light, and humidity control. Maintaining appropriate storage parameters ensures peptide integrity from arrival through long-term research schedules.

Q: How should lyophilized CJC-1295 (No DAC) be stored upon arrival? A: Upon receipt, lyophilized CJC-1295 (No DAC) vials should be stored in a freezer at -20°C (-4°F) for short-to-medium term storage, or -80°C (-112°F) for long-term storage up to 24 months. Desiccated containers protect the cake from atmospheric moisture absorption.

Q: What is the shelf life of reconstituted CJC-1295 (No DAC) in solution? A: Once reconstituted with bacteriostatic water, liquid CJC-1295 (No DAC) solution should be refrigerated at 2°C to 8°C (36°F to 46°F) and used within 21 to 28 days. Avoid repeated freeze-thaw cycles, as physical shear forces can cause peptide aggregation and loss of bioactivity.

7. Shipping Protocols and Institutional Sourcing

PX1 Research operates dedicated fulfillment hubs in California and Arizona to guarantee fast, secure dispatch of scientific reagents. Institutional accounts and high-volume procurement teams can request specialized bulk packaging via our wholesale portal.

Q: What shipping methods are used for CJC-1295 (No DAC) orders? A: Orders ship directly from our California and Arizona fulfillment centers. PX1 Research provides same-day shipping for orders placed before 12:00 PM PST, Monday through Friday. Cold-pack insulated shipping options ensure structural stability during transit across diverse climate conditions.

Q: Are bulk quantities and laboratory volume accounts available? A: Yes. Universities, biotechnology firms, and institutional research facilities requiring volume procurement can set up institutional accounts through our wholesale catalog. Bulk lots receive dedicated analytical testing, customizable vial sizes, and batch-reserved inventory support.

8. Comparative Analysis & Laboratory Compliance

When evaluating GHRH secretagogues for tissue repair or somatotrope activation, researchers often compare CJC-1295 (No DAC) against related compounds within the secretagogue family. Detailed mechanisms and kinetic profiles are detailed in our comprehensive research library.

In secretagogue research, CJC-1295 (No DAC) is frequently investigated alongside selective ghrelin receptor agonists such as Ipamorelin or traditional growth hormone secretagogues like GHRP-2. Comparing these molecules allows researchers to evaluate synergistic GHRH/GHRP co-activation, evaluating how dual pathway stimulation influences natural GH pulse amplitude in preclinical models.

Q: How does CJC-1295 (No DAC) differ from GHRH secretagogues like Ipamorelin? A: CJC-1295 (No DAC) acts specifically as a GHRH receptor agonist, while Ipamorelin targets the growth hormone secretagogue receptor (GHSR-1a). In preclinical research, combining a GHRH agonist with a GHRP agonist yields a synergistic increase in pulsatile growth hormone release beyond single-compound activation.

Q: Is CJC-1295 (No DAC) permitted for human or clinical use? A: No. CJC-1295 (No DAC) provided by PX1 Research is strictly sold as a research chemical for laboratory research use only (RUO). It is not intended for human or veterinary administration, medical treatment, diagnostic procedures, or therapeutic applications under any circumstances.